Richard Holland

Richard Holland PhD is a seasoned professional in the field of medicinal chemistry, currently serving as Senior Director of Chemistry (Technology Development) at Genevant Sciences since April 2018, where responsibilities include leveraging expertise in nucleic acids as therapeutic agents. Previously, Richard held various positions at Arbutus Biopharma Corporation, including Director of Chemistry, focusing on the design and synthesis of proprietary targeting ligands for Hepatitis B therapies. Additional experience includes consulting for early-stage businesses, ownership of Holland Days Investments Inc., and leadership roles at Zalicus Pharmaceuticals and Neuromed Pharmaceuticals. Richard's educational background includes a PhD in Cancer Research and Medicinal Chemistry from The Institute of Cancer Research and a B.Sc. in Chemistry from The University of Manchester, complemented by culinary training.